CPSE:GMAB
CPSE:GMABBiotechs

Genmab (CPSE:GMAB) Valuation Check As Anthropic AI Alliance Supports Late Stage Pipeline Progress

Why Genmab’s AI alliance with Anthropic matters for shareholders Genmab (CPSE:GMAB) has entered an alliance with Anthropic to bring Claude powered AI agents into its research and clinical development work, aiming to speed up data heavy tasks and tighten operational workflows. For you as an investor, the key angle is how this use of AI could influence Genmab’s ability to progress its late stage antibody medicines through clinical and regulatory steps, potentially affecting timelines, costs,...
CPSE:ROCK B
CPSE:ROCK BBuilding

Rockwool (CPSE:ROCK B) Is Down 7.6% After Russian Assets Put Under External Management – Has The Bull Case Changed?

In early 2026, a Russian presidential decree placed ROCKWOOL’s Russian subsidiary under external management, stripping the company of control over four local factories and prompting immediate deconsolidation of these entities from its accounts, while ROCKWOOL pursues legal remedies under the Russia–Denmark Bilateral Investment Treaty. This loss of control over Russian assets materially reshapes ROCKWOOL’s geographic footprint and risk profile, raising fresh questions about its exposure to...
CPSE:BAVA
CPSE:BAVABiotechs

Will Bavarian Nordic's (CPSE:BAVA) New 10% Buyback Shift Its Vaccine-Focused Investment Narrative?

Bavarian Nordic A/S has begun a shareholder-authorized buyback program as of January 7, 2026, allowing repurchases of up to 10% of its share capital on Nasdaq Copenhagen at prices within 10% of the prevailing market price, with the mandate running through December 31, 2026. This move to retire shares adds a new capital allocation element that could influence how investors view Bavarian Nordic’s earnings profile and ownership structure. We’ll now examine how this newly launched share...
CPSE:JYSK
CPSE:JYSKBanks

Why Jyske Bank (CPSE:JYSK) Is Up 8.0% After Lifting Its 2025 Profit Guidance – And What's Next

Jyske Bank A/S recently raised its 2025 earnings guidance, now expecting a net profit of about DKK 5.40 billion and earnings per share of around DKK 85, supported by broad-based business momentum and favorable financial markets. The upgrade, correcting a prior clerical error in its tables, highlights how stronger-than-expected activity across the bank’s operations is feeding through to higher projected profitability. We’ll now explore how this higher 2025 profit outlook could reshape Jyske...
CPSE:BO
CPSE:BOConsumer Durables

Bang & Olufsen (CPSE:BO) Loss Deepens In Q2 2026 Testing Turnaround Narrative

Q2 2026 results snapshot Bang & Olufsen (CPSE:BO) has just posted Q2 2026 revenue of DKK 676 million, with basic EPS of DKK 0.40 loss and net income loss of DKK 53 million setting the tone for the quarter. The company has seen quarterly revenue move between DKK 544 million and DKK 698 million over the last six reported periods, while basic EPS has ranged from a profit of DKK 0.06 to a loss of DKK 0.40. This gives investors a clear view of how top line stability contrasts with ongoing earnings...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Is Novo Nordisk (CPSE:NOVO B) Pricing In Future Growth From Weight Loss Therapies?

If you are wondering whether Novo Nordisk shares are offering good value right now, looking at how the current price lines up with different valuation methods can give you a clearer picture. The stock last closed at DKK 378.25, with returns of 3.2% over 7 days, 19.5% over 30 days, 14.5% year to date, a 35.7% decline over 1 year, a 17.2% decline over 3 years, and 85.9% over 5 years. This sets a mixed backdrop for assessing where value might sit today. Recent news around Novo Nordisk has...
CPSE:NKT
CPSE:NKTElectrical

How Investors May Respond To NKT (CPSE:NKT) Expanding Into High‑Voltage Dry‑Type Grid Terminations

NKT recently launched the KFEV 245 dry-type outdoor termination for 245 kV power cable systems, aiming to replace conventional oil-filled terminations with a safer, simpler and more environmentally friendly solution manufactured at its Alingsås, Sweden, centre of excellence. This product broadens NKT’s high-voltage accessories portfolio across the full HVAC range up to 550 kV, reinforcing its ability to meet growing customer demand for reliable, sustainable grid components. We’ll now examine...
CPSE:VWS
CPSE:VWSElectrical

Assessing Vestas Wind Systems (CPSE:VWS) Valuation After New Global Turbine Orders And Share Price Rebound

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after disclosing new turbine orders across Europe, North America, and Australia, covering more than 1,000 MW of capacity under long term service agreements. See our latest analysis for Vestas Wind Systems. These multi region turbine orders arrive after a strong run in the shares, with a 90 day share price return of 41.07% and a 1 year total shareholder return of 93.52%. However, the 3 and 5 year total shareholder returns of 14.36%...
CPSE:ORSTED
CPSE:ORSTEDRenewable Energy

Does Court Greenlight For Revolution Wind Transform The Bull Case For Ørsted (CPSE:ORSTED)?

A U.S. federal judge recently cleared Danish offshore wind developer Ørsted to resume work on its nearly completed, US$5.00 billion Revolution Wind project off Rhode Island and Connecticut, overturning a Trump administration halt that cited national security concerns. The ruling materially reduces the risk of cancellation for a major U.S. offshore wind asset, reinforcing the legal and regulatory contours shaping Ørsted’s American growth ambitions. We’ll now examine how the court’s reversal...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Novo Nordisk (CPSE:NOVO B) Is Up 5.3% After U.S. Launch Of Oral Wegovy Pill - Has The Bull Case Changed?

Novo Nordisk has launched its FDA-approved oral Wegovy pill in the U.S., rapidly widening access through major pharmacies, Amazon Pharmacy, and telehealth platforms as the first GLP-1 pill for chronic weight management and cardiovascular risk reduction. This shift toward a once-daily pill, backed by phase 3 data and expanding distribution partnerships, could materially influence how patients choose between oral and injectable GLP-1 therapies in obesity care. We’ll now examine how the broad...
CPSE:GN
CPSE:GNConsumer Durables

How Investors May Respond To GN Store Nord (CPSE:GN) Quiet Turnaround In Audio And Hearing Tech

In recent months, GN Store Nord A/S has been working to rebuild its position in audio and hearing technology by tightening costs, integrating operations more effectively, and continuing to develop its Jabra and hearing-aid product lines. This quieter turnaround effort matters because it ties GN’s professional and medical audio strengths directly to persistent trends in remote work and age-driven hearing care demand. We’ll now examine how GN Store Nord’s renewed emphasis on cost savings and...
CPSE:DANSKE
CPSE:DANSKEBanks

Does Danske Bank’s Expanded Buy-back and New AI Hub Shift Its Strategic Focus (CPSE:DANSKE)?

Danske Bank has continued its DKK 5.00 billion share buy-back programme, having repurchased 18,155,560 shares so far, while also appointing Dr Fiona Browne as its first Head of AI to lead a new AI centre of excellence in Belfast. Together, the ongoing buy-back and creation of a dedicated AI leadership role highlight Danske Bank’s twin focus on capital return discipline and building in-house technological capabilities. We’ll now examine how the expanding share buy-back and new AI centre of...
CPSE:PNDORA
CPSE:PNDORALuxury

Pandora (CPSE:PNDORA) Valuation After 2025 Growth Cut And Weaker US Holiday Demand

Pandora (CPSE:PNDORA) cut its 2025 sales growth forecast to 6% after weaker than expected US holiday spending, while shares dropped 10% as the new CEO highlighted soft North American sentiment and rising silver costs. See our latest analysis for Pandora. The 13% one day share price decline and 26.3% 90 day share price return, together with a 55% drop in one year total shareholder return, suggest momentum has been fading even though three and five year total shareholder returns remain...
CPSE:PNDORA
CPSE:PNDORALuxury

Is Pandora (CPSE:PNDORA) Now Attractively Priced After A 55% One Year Share Price Slide?

You may be wondering if Pandora is starting to look like value after a tough run, or if the risks still outweigh the potential reward for you as a shareholder or watchlist follower. The stock last closed at DKK 588.4, after a 15.4% decline over 7 days, a 16.8% decline over 30 days, a 15.4% decline year to date and a 55.0% decline over the past year, while the 3 year and 5 year returns sit at 10.7% and 6.8% respectively. Recent price moves have come alongside ongoing market attention on...
CPSE:DEMANT
CPSE:DEMANTMedical Equipment

Assessing Demant (CPSE:DEMANT) Valuation As AI-Focused Hearing Devices Draw Fresh Investor Interest

Recent coverage around Demant (CPSE:DEMANT) has centered on its push into AI-powered, lifestyle-focused hearing devices and a broad footprint across hearing aids, diagnostics, and audio communications, which appears to be supporting current investor interest. See our latest analysis for Demant. At a share price of DKK 223.8, Demant has seen short term momentum pick up, with a 1 month share price return of 3.4% and a year to date share price gain of 4.9%. However, the 1 year total shareholder...